Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A

NCT00157157 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT00157157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00157157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A
Lead sponsor
Baxalta now part of Shire
Phase
Phase 3
Overall status
Completed
Start date
April 1, 2004
Completion date
September 11, 2009
Enrollment
66 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a